A Phase 1 b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed metastatic colorectal adenocarcinoma. 2) Must have at least 1 measurable lesion per RECIST v1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 3) Life expectancy at least 3 months. 4) Adequate hematologic and end-organ function Negative HIV, Hep B and Hep C antibody testing.

You may not be eligible for this study if the following are true:

  • 1) Previous anticancer treatment within 4 weeks prior to initiation of study treatment. 2) Prior allogeneic stem cell or solid organ transplant. 3) Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment. 4) Use of any live vaccines against infectious diseases within 28 days of first dose.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.